Hologic
(Nasdaq: HOLX)
shares remained relatively unmoved this morning on third-quarter results that beat the Wall Street forecast.
Shares of HOLX rose 0.1% to $74.14 apiece in early-morning trading today.
The Marlborough, Massachusetts-based women’s health and diagnostics company reported profits of $187.3 million. That equals 83¢ per share on sales of $1.05 billion for the three months ended Sept. 27, 2025.
Hologic recorded a 4.9% bottom-line gain on a sales increase of 6.2%.
Adjusted to exclude one-time items, earnings per share came in at $1.13. That landed 3¢ ahead of expectations on Wall Street. Sales also topped the forecast as experts projected $1.03 billion in revenue.
Hologic reported $454.1 million in Diagnostics revenue, marking a 2.4% increase year-over-year. Higher core U.S. molecular diagnostic sales drove growth, partially offset by lower COVID-19 assay sales and lower sales in China.
Breast Health delivered $393.7 million in sales for 4.8% growth. Interventional products drove growth there, with the company noting the inclusion of Endomagnetics and continued U.S. sales improvements.
Surgical revenues grew 10.2% to $172.5 million, driven primarily by increased MyoSure and Fluent sales, plus the recently acquired Gynesonics business.
The company also shared that its non-GAAP gross margin of 60.9% decreased 60 basis points, primarily due to product mix and increased tariff expenses.
Notably, Hologic recently agreed to be acquired by funds managed by private equity firms Blackstone and TPG for up to $18.3 billion. As a result, the company said it is not providing annual or quarterly financial guidance for fiscal year 2026, and will not host a conference call to discuss its fourth quarter 2025 financial results.
